COMBINATION OF CHEMOTHERAPY AND HORMONE-THERAPY IN ADVANCED BREAST-CANCER

被引:0
|
作者
MERKLE, E [1 ]
BAR, I [1 ]
HENKE, A [1 ]
BUHNER, M [1 ]
WILDT, L [1 ]
MARTUS, P [1 ]
LANG, N [1 ]
机构
[1] UNIV ERLANGEN NURNBERG,INST MED STAT & DOKUMENTAT,W-8520 ERLANGEN,GERMANY
关键词
ADVANCED BREAST CANCER; COMBINED THERAPY; DECAPEPTYL(R); RESPONSE RATE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a prospective study at the Department of Obstetrics and Gynaecology, University of Erlangen, patients with advanced breast carcinoma were treated with a combination of chemotherapy and hormone therapy. Patients received one injection of Decapeptyl(R) in a 28 days interval. At day 12 and 13 of the treatment cycle 40 mug of ethinylestradiol were applicated followed by intravenous chemotherapy with 500 mg/m2 fluorouracil, 10 mg/m2 mitoxantrone and 500 mg/m2 cyclophosphamide took place on day 14. 39 patients were integrated in this study. All of these patients were evaluable regarding the side-effects and 36 patients concerning the response rate. In case of response after 6 cycles the interval between the chemotherapy was prolonged to 6 weeks and the Decapeptyl(R) injections remained in a 4 weeks interval. 15 patients received this combined therapy as a first-line therapy, 24 patients as a second-line therapy or third-line therapy. 2 patients had a complete remission, 14 patients had a partial remission. The objective response rate (CR+PR) was therefore 44 %. In 8 patients the response was classified as no change, consequently the total response rate (CR + PR + NC) was 67 %. 12 patients showed a progression (33 %), 2 patients with several previous treatments suffered an early progress. 3 patients did not finish the therapy. The median response duration was 9 months and the median follow up time until now is 13 months; 24 patients died. Therapy related side-effects were tolerable. As the most frequent side-effect bone marrow suppression were observed. Subjective, for the patients most inconvenient side-effects like nausea, vometing, and alopecia seldomly appeared. The combination of chemotherapy and hormone therapy achieved with a good toleration response rates, which are compatible to international standards of chemotherapy. The exspectations to achieve a better remission rate by a combination of chemotherapy and hormone therapy rather than chemotherapy alone were not fulfilled in this studie.
引用
收藏
页码:220 / 223
页数:4
相关论文
共 50 条
  • [11] THE DESIGN OF ADVANCED BREAST-CANCER TRIALS - NEW APPROACHES
    FRASER, SCA
    EBBS, SR
    DOBBS, HJ
    FALLOWFIELD, LJ
    BAUM, M
    ACTA ONCOLOGICA, 1990, 29 (03) : 397 - 400
  • [12] MAMMARY SERUM ANTIGEN (MSA) IN ADVANCED BREAST-CANCER
    SMART, YC
    STEWART, JF
    BARTLETT, LD
    BRIEN, JH
    FORBES, JF
    BURTON, RC
    BREAST CANCER RESEARCH AND TREATMENT, 1990, 16 (01) : 23 - 28
  • [13] A PHASE-II TRIAL OF WEEKLY HIGH-DOSE FOLINIC ACID AND 5-FLUOROURACIL IN COMBINATION WITH EPIRUBICIN AS SALVAGE CHEMOTHERAPY IN ADVANCED BREAST-CANCER
    STOGER, H
    SCHMID, M
    BAUERNHOFER, T
    MOSER, R
    PLONER, F
    DERSTVENSCHEG, E
    KASPAREK, AK
    KUSS, I
    WILDERSTRUSCHNIG, M
    LACKNER, C
    STEINDORFER, P
    SAMONIGG, H
    ONCOLOGY, 1994, 51 (06) : 518 - 522
  • [14] Current combination chemotherapy regimens for metastatic breast cancer
    Schwartz, Joanna
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (23) : S3 - S8
  • [15] A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer
    Cope, Shannon
    Zhang, Jie
    Saletan, Stephen
    Smiechowski, Brielan
    Jansen, Jeroen P.
    Schmid, Peter
    BMC MEDICINE, 2014, 12
  • [16] A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer
    Shannon Cope
    Jie Zhang
    Stephen Saletan
    Brielan Smiechowski
    Jeroen P Jansen
    Peter Schmid
    BMC Medicine, 12
  • [17] COMBINATION CHEMOTHERAPY WITH CMF (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL) VERSUS CNF (MITOXANTRONE, 5-FLUOROURACIL, CYCLOPHOSPHAMIDE) IN ADVANCED BREAST-CANCER - A MULTICENTER RANDOMIZED STUDY
    LORUSSO, V
    VICI, P
    BIANCO, AR
    LOPEZ, M
    DEPLACIDO, S
    PIANO, A
    PALOMBA, G
    CARLOMAGNO, C
    DAPRILE, M
    FOSSER, V
    BRANDI, M
    DELENA, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1993, 2 (04) : 531 - 535
  • [19] Steroid hormone levels in patients with advanced breast cancer during therapy with droloxifene: A pilot study
    Dalski, J
    Gorlich, M
    TUMORI JOURNAL, 1996, 82 (01): : 45 - 47
  • [20] CISPLATIN AND RECOMBINANT ALPHA-INTERFERON IN ADVANCED BREAST-CANCER
    PRONZATO, P
    BERTELLI, G
    AMOROSO, D
    GOZZA, A
    ZANIBONI, A
    MARINI, G
    ROSSO, R
    ANNALS OF ONCOLOGY, 1990, 1 (02) : 150 - 151